Aptevo Therapeutics Inc
APVO4.720USD
+0.020+0.43%
Cierre 05/30, 16:00（ET）Cotizaciones retrasadas 15 min
6.88MCap. mercado
PérdidaP/E TTM
Más Datos de Aptevo Therapeutics Inc Compañía
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Información de la empresa
Código de la empresaAPVO
Nombre de la empresaAptevo Therapeutics Inc
Fecha de salida a bolsaJul 20, 2016
Fundada en2016
Director ejecutivoMr. Marvin L. White
Número de empleados37
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 20
Dirección2401 4th Ave Ste 1050
CiudadSEATTLE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal98121-3460
Teléfono12068380500
Sitio Webhttps://aptevotherapeutics.com/
Código de la empresaAPVO
Fecha de salida a bolsaJul 20, 2016
Fundada en2016
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
7.00
--
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
5.00
--
Dr. John E. Niederhuber, M.D.
Dr. John E. Niederhuber, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.00
--
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.00
+50.00%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
2.00
--
Ms. So Young Kwon
Ms. So Young Kwon
Senior Vice President, General Counsel, Business Development and Corporate Affairs
Senior Vice President, General Counsel, Business Development and Corporate Affairs
--
--
Ms. Daphne L. Taylor
Ms. Daphne L. Taylor
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Daniel J. Abdun-Nabi, J.D.
Mr. Daniel J. Abdun-Nabi, J.D.
Independent Director
Independent Director
--
--
Mr. Grady Grant, III
Mr. Grady Grant, III
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
7.00
--
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
5.00
--
Dr. John E. Niederhuber, M.D.
Dr. John E. Niederhuber, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.00
--
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.00
+50.00%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
2.00
--
Ms. So Young Kwon
Ms. So Young Kwon
Senior Vice President, General Counsel, Business Development and Corporate Affairs
Senior Vice President, General Counsel, Business Development and Corporate Affairs
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: mié., 28 de may
Hora de actualización: mié., 28 de may
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
L1 Capital Global Opportunities Master Fund Ltd.
3.11%
Bigger Capital Funds, LP
1.48%
Heights Capital Management, Inc.
1.48%
Geode Capital Management, L.L.C.
0.08%
Schiketanz Capital Advisors GmbH
0.04%
Other
93.81%
Estadísticas de accionistas
Accionista
Proporción
L1 Capital Global Opportunities Master Fund Ltd.
3.11%
Bigger Capital Funds, LP
1.48%
Heights Capital Management, Inc.
1.48%
Geode Capital Management, L.L.C.
0.08%
Schiketanz Capital Advisors GmbH
0.04%
Other
93.81%
Tipo
Accionista
Proporción
Corporation
3.11%
Investment Advisor
1.52%
Hedge Fund
1.50%
Investment Advisor/Hedge Fund
0.08%
Research Firm
0.04%
Other
93.75%
Participación institucional
Hora de actualización: lun., 24 de feb
Hora de actualización: lun., 24 de feb
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
49
55.12K
0.94%
-14.63K
2024Q4
49
48.74K
3.37%
-20.87K
2024Q3
46
34.83K
7.56%
-18.81K
2024Q2
48
53.21K
48.29%
+52.02K
2024Q1
49
188.00
1.03%
-1.27K
2023Q4
51
1.27K
10.69%
-1.06K
2023Q3
56
2.18K
24.99%
+1.07K
2023Q2
60
629.00
13.58%
-1.76K
2023Q1
67
602.00
13.71%
-1.90K
2022Q4
74
629.00
16.12%
-1.81K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Tower Research Capital LLC
1.09K
0.03%
+408.00
+60.18%
Dec 31, 2024
SBI Securities Co., Ltd.
131.00
0%
+131.00
--
Dec 31, 2024
The Vanguard Group, Inc.
56.00
0%
--
--
Jan 31, 2025
Ver más
ETFs relacionados
Hora de actualización: mar., 6 de may
Hora de actualización: mar., 6 de may
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Fecha
Tipo
Relación
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 26, 2020
Merger
14<1
Mar 26, 2020
Merger
14<1
Ver más
